Summary

The global Pathology Slide Digitization Service market is projected to grow from US$ 261 million in 2025 to US$ 496 million by 2032, at a CAGR of 9.7% (2026-2032), driven by critical product segments and diverse end‑use applications.
Pathology Slide Digitization Service refers to professional commercial services that convert physical pathology glass slides into high-resolution digital images, primarily whole slide images (WSI), for viewing, storage, sharing, remote review and computational analysis. The service typically covers slide accessioning and barcode registration, scan-parameter configuration, automated image acquisition, focusing and stitching, image quality control, rescanning when required, metadata association, file processing, secure transfer and digital delivery. Depending on specimen and project requirements, service capabilities may cover conventional 20× or 40× brightfield scanning for H&E and IHC slides, fluorescence and FISH imaging, multiplex imaging, Z-stack acquisition, tissue microarrays and large-format or whole-mount slides. Commercial delivery models range from centralized mail-in scanning and high-volume archival conversion to on-site project scanning and managed scanning services. The principal customers include pharmaceutical and biotechnology companies, CROs, hospitals and pathology laboratories, academic research institutions, biobanks and organizations developing digital pathology or computational pathology applications. The market focuses on professional service activities that transform existing physical slides into standardized, quality-controlled and usable digital pathology assets.
Key Findings
North America represents the largest commercial market for Pathology Slide Digitization Service
Routine brightfield whole slide imaging accounts for the largest physical scanning volume
Pharmaceutical biotechnology and CRO customers represent a major high-value demand group
The confirmed core supplier pool contains approximately 40 commercial service providers worldwide
The market remains fragmented beyond a limited group of scaled enterprise and specialist providers
Market Trends
Pathology Slide Digitization Service is moving from basic scan-only outsourcing toward managed digital pathology workflows that combine slide tracking, automated quality control, metadata management, secure image delivery and increasingly long-term digital asset management. Routine 20× and 40× brightfield WSI remains the volume foundation of the market, but higher-value demand is shifting toward fluorescence, FISH, multiplex imaging, Z-stack acquisition, large-format slides and projects requiring more rigorous image QC and data governance. Another important development is the transition from one-off mail-in scanning toward on-site project scanning and managed service models, particularly for customers with large historical archives or temporary capacity requirements. Digital images are also becoming more valuable as reusable data assets for computational pathology and AI development, which is encouraging customers to place greater emphasis on image consistency, standardized metadata and interoperability rather than scanning speed alone. Iron Mountain's digital pathology offering illustrates the integration of physical slide custody, digitization and digital archive access, while industry technology providers are increasingly positioning scanning as part of broader digital pathology infrastructure rather than a standalone conversion step.
Market Dynamics
Drivers
Demand is being supported by the continued adoption of whole slide imaging across pathology research, pharmaceutical development and selected clinical workflows, together with the growing need to convert large physical slide collections into searchable digital assets. Pharmaceutical and biotechnology companies increasingly use digitized slides in preclinical studies, toxicologic pathology, biomarker programs and distributed pathology review, while hospitals and laboratories are digitizing selected workflows to facilitate remote collaboration and faster access to archived material. Regulatory and professional frameworks are also becoming more established: the FDA has issued guidance covering technical performance assessment of digital WSI devices and the use of WSI in GLP-compliant nonclinical toxicology studies, while the College of American Pathologists maintains an active guideline for validation of WSI used for diagnostic purposes. These developments improve confidence in standardized digital pathology workflows and indirectly expand the addressable demand for professional scanning services.
Restraints
The main constraint is the increasing ability of large hospitals, pathology laboratories, pharmaceutical companies and CROs to purchase high-throughput scanners and develop internal digitization capacity. As scanner throughput improves and automation reduces labor requirements, routine brightfield scanning becomes easier to internalize, placing downward pressure on outsourced per-slide pricing. High-volume archival projects can also command significantly lower unit prices than small research projects, limiting margin expansion for providers focused only on basic scanning. In addition, very large WSI files create substantial storage, networking and data-management requirements, while physical slide logistics, chain-of-custody procedures, damaged or poorly prepared slides and rescanning can materially affect service efficiency. The economics therefore favor providers able to combine scale, automation and workflow management rather than businesses relying solely on manual low-volume scanning.
Opportunities
The strongest opportunities are emerging in large-scale archival conversion, pharmaceutical and biotechnology R&D, clinical trials, toxicologic pathology and AI-ready dataset creation. Many organizations possess substantial historical slide collections that are scientifically valuable but difficult to search, share or analyze while retained only in physical form, creating opportunities for multi-year digitization programs. Managed scanning and on-site service models can also address customers that want access to digital pathology capacity without permanently building peak internal infrastructure. Higher-value technical opportunities exist in fluorescence, multiplex imaging, FISH, Z-stack and large-format slide scanning, where equipment requirements, image-acquisition complexity and QC demands are higher than in routine brightfield work. As computational pathology applications expand, providers that can deliver standardized images, reliable metadata and structured digital archives should be positioned to capture a larger share of customer value than scan-only suppliers.
Challenges
Long-term competition will increasingly depend on service quality and data reliability rather than simple access to scanning hardware. Providers must maintain consistent focus, tissue coverage, color reproduction and image completeness across large and heterogeneous slide collections, while managing difficult specimens and minimizing rescans. Clinical and regulated research applications also require stronger documentation, validation, information security and retention practices than routine academic projects. CAP guidance emphasizes validation and concordance when WSI is used for diagnostic purposes, and FDA guidance for nonclinical toxicology highlights documentation and management requirements for WSI used in GLP studies. At the same time, customers increasingly expect interoperability with image-management systems, computational pathology tools and enterprise data environments. Providers unable to invest in automation, QC, cybersecurity and standardized data workflows may therefore face increasing difficulty competing for enterprise-scale projects.
Value Chain Analysis
The value chain of Pathology Slide Digitization Service begins with physical pathology slides and associated specimen information generated by hospitals, diagnostic laboratories, CROs, pharmaceutical research programs and academic institutions. Upstream inputs primarily consist of whole slide scanners, imaging optics, fluorescence modules, computing and storage infrastructure, barcode and slide-tracking systems, image-management software, cloud or data-center capacity and skilled technical personnel. The central service layer creates value through accessioning, slide preparation checks, parameter configuration, high-throughput image acquisition, automated and manual quality control, rescanning, metadata reconciliation, file conversion, secure transfer and, in more integrated models, digital archive management. Downstream customers consume the resulting images for pathology review, pharmaceutical research, toxicology, clinical trial workflows, remote collaboration, education, computational pathology and AI model development. Basic brightfield scanning has a relatively standardized value proposition and is increasingly exposed to price competition, whereas complex imaging, regulated workflows, high-volume archive migration, on-site managed scanning and data-management services provide stronger differentiation. As a result, value capture is gradually moving away from the physical act of scanning toward reliable workflow execution, quality assurance, traceability, information security and integration of digital slides into reusable pathology data assets.
Segment Insights
By imaging modality, brightfield whole slide imaging remains the largest segment in physical slide volume because H&E, conventional IHC and other routine histology slides constitute the majority of digitization workloads. Fluorescence WSI, FISH, multiplex imaging and Z-stack scanning account for a smaller share of slides but typically carry higher service value because acquisition time, file size, instrument requirements and QC complexity are substantially greater. Large-format and whole-mount slides represent another specialized segment where fewer providers possess suitable equipment and workflow experience. Consequently, routine brightfield scanning provides the industry's volume base, while specialty imaging contributes disproportionately to revenue per slide and service differentiation.
By delivery model, centralized off-site scanning remains the most established approach for research projects and manageable physical slide collections, whereas on-site project scanning and managed scanning are becoming more relevant for large archives, sensitive material and customers seeking to avoid significant internal capital expenditure or temporary capacity expansion. By customer type, pharmaceutical, biotechnology and CRO projects are among the most attractive commercial segments because digitization can be integrated into preclinical research, toxicology, biomarker development and clinical trial workflows. Hospitals and pathology laboratories represent substantial long-term potential, but their outsourcing rate varies because larger institutions can justify internal scanner investment. Academic and research customers remain important in project volume but are generally more price-sensitive and fragmented.
Downstream Market Opportunities
The most attractive downstream opportunity lies in customers for whom digital slides provide value beyond simple remote viewing. Pharmaceutical and biotechnology companies increasingly need standardized digital pathology data that can support cross-site review, longitudinal research programs, biomarker analysis and computational pathology. Hospitals and pathology laboratories offer substantial opportunities in historical archive conversion, backlog reduction and temporary capacity support, particularly where complete internal digitization would require significant capital investment and operational change. Biobanks and repositories can unlock previously inaccessible physical slide collections through systematic digitization, while AI and computational pathology developers require large, consistent and well-annotated image datasets. These applications increase demand not only for scanning volume but also for image QC, metadata integrity, reproducibility and reliable digital delivery, improving the commercial potential of higher-value integrated service models.
Regional Insights
North America is the largest commercial market and has the broadest supplier structure, combining specialist scanning providers, pathology and histology CROs, archive-management companies and digital pathology technology businesses. The region benefits from a large pharmaceutical and biotechnology research base, extensive pathology archives and relatively early adoption of WSI. Europe represents the second major commercial cluster, with particularly visible activity in the United Kingdom, Germany, Ireland and Belgium, supported by pharmaceutical research, contract pathology and established digital pathology adoption. These two regions also contain most of the scaled enterprise providers identified in the core supplier pool.
Asia-Pacific is structurally more fragmented. China has a sizeable number of regional research-service companies offering pathology slide scanning, often bundled with tissue processing, staining, immunohistochemistry or image analysis, but individual suppliers are generally smaller and basic research scanning is more price competitive. Japan has a relatively established market for virtual slide creation and contract pathology services, while Taiwan has several specialized WSI and slide-scanning service companies. South Korea, Southeast Asia and parts of India currently have fewer independently scaled commercial providers, with a greater proportion of scanning capacity located within hospitals, universities, public research platforms or equipment distribution networks. This creates longer-term opportunities for specialist outsourcing as digital pathology workloads expand.
Competitive Landscape Analysis
The competitive landscape of Pathology Slide Digitization Service is fragmented, with a limited group of scaled providers operating alongside numerous pathology CROs and regional specialists. Competition is shaped less by exclusive access to scanner technology than by throughput, image quality, project execution, slide logistics, quality-control systems, metadata integrity, information security and the ability to handle large or technically difficult collections. Enterprise providers differentiate through high-volume archival programs, managed scanning, global research relationships or integration with physical archive and data-management infrastructure, while pathology CROs compete through end-to-end workflows that combine histology, staining, scanning, pathology review and image analysis. Regional specialists compete on flexibility, local turnaround time and cost. Strategic consolidation is also broadening competitive capabilities: EVIDENT completed its acquisition of Pramana in August 2025, combining digital pathology scanning technology with a larger imaging platform, while Sartorius completed the acquisition of MatTek, including Visikol, in July 2025, expanding its drug-development and advanced imaging capabilities. These transactions support a broader industry shift from isolated scanning services toward integrated sample-to-image-to-data workflows. Over time, routine brightfield scanning is likely to become more standardized and price-sensitive, while enterprise archive migration, managed services, specialty imaging, regulated research workflows and AI-ready data preparation should become more important sources of differentiation.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Pathology Slide Digitization Service market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Iron Mountain Incorporated
EVIDENT Corporation (Pramana)
Deciphex
HistoWiz, Inc.
3DHISTECH Ltd.
Huron Technologies International Inc.
CellCarta
Charles River Laboratories International, Inc.
Labcorp Holdings Inc.
Source BioScience
StageBio
Sartorius AG
HistologiX
iHisto
Digital Pathology Services
IDEXX Laboratories, Inc.
Inotiv, Inc.
Propath
EPL, Inc.
iBioSpecimen
Meyer Instruments, Inc.
Precision for Medicine
Aragen Bioscience, Inc.
LLS ROWIAK LaserLabSolutions GmbH
NationWide Laboratories
ABS Bio, Inc.
Medmain Inc.
BioSpective Inc.
Genostaff Co., Ltd.
BEIJING BIOSYNTHESIS BIOTECHNOLOGY CO., LTD.
Affinity Biosciences LTD
C-Path BV
GENOSS Co., Ltd.
Fukushima Cell Factory Co., Ltd.
Mediridge Co., Ltd.
BioPioneer
Toson Technology Co., Ltd.
Tian You International Co., Ltd.
Segment by Type
Brightfield Whole Slide Imaging
Fluorescence Whole Slide Imaging
Multispectral Imaging
Others
Segment by Service Delivery Model
Centralized Batch Scanning
On-site Project Scanning
Managed Scanning
Others
Segment by Specimen and Slide Type
Histology Tissue Slides
Cytology and Hematology Slides
Tissue Microarrays
Others
Segment by Application
Preclinical and Clinical Trials
Clinical Workflow and Consultation Support
Archival Digitization
Others
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Pathology Slide Digitization Service study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Pathology Slide Digitization Service: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Pathology Slide Digitization Service Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Brightfield Whole Slide Imaging
1.2.3 Fluorescence Whole Slide Imaging
1.2.4 Multispectral Imaging
1.2.5 Others
1.3 Market Segmentation by Service Delivery Model
1.3.1 Global Pathology Slide Digitization Service Market Size by Service Delivery Model, 2021 vs 2025 vs 2032
1.3.2 Centralized Batch Scanning
1.3.3 On-site Project Scanning
1.3.4 Managed Scanning
1.3.5 Others
1.4 Market Segmentation by Specimen and Slide Type
1.4.1 Global Pathology Slide Digitization Service Market Size by Specimen and Slide Type, 2021 vs 2025 vs 2032
1.4.2 Histology Tissue Slides
1.4.3 Cytology and Hematology Slides
1.4.4 Tissue Microarrays
1.4.5 Others
1.5 Market Segmentation by Application
1.5.1 Global Pathology Slide Digitization Service Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Preclinical and Clinical Trials
1.5.3 Clinical Workflow and Consultation Support
1.5.4 Archival Digitization
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Executive Summary
2.1 Global Pathology Slide Digitization Service Revenue Estimates and Forecasts (2021-2032)
2.2 Global Pathology Slide Digitization Service Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competitive Landscape
3.1 Global Pathology Slide Digitization Service Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Pathology Slide Digitization Service Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Brightfield Whole Slide Imaging: Market Share by Key Players
3.3.2 Fluorescence Whole Slide Imaging: Market Share by Key Players
3.3.3 Multispectral Imaging: Market Share by Key Players
3.3.4 Others: Market Share by Key Players
3.4 Global Pathology Slide Digitization Service Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Product Segmentation
4.1 Global Pathology Slide Digitization Service Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Pathology Slide Digitization Service Market by Service Delivery Model
4.2.1 Global Revenue by Service Delivery Model (2021-2032)
4.2.2 Global Revenue-Based Market Share by Service Delivery Model (2021-2032)
4.3 Global Pathology Slide Digitization Service Market by Specimen and Slide Type
4.3.1 Global Revenue by Specimen and Slide Type (2021-2032)
4.3.2 Global Revenue-Based Market Share by Specimen and Slide Type (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Downstream Applications and Customers
5.1 Global Pathology Slide Digitization Service Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Pathology Slide Digitization Service Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Pathology Slide Digitization Service Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico
7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Pathology Slide Digitization Service Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Pathology Slide Digitization Service Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Pathology Slide Digitization Service Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Pathology Slide Digitization Service Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Pathology Slide Digitization Service Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Pathology Slide Digitization Service Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Pathology Slide Digitization Service Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Pathology Slide Digitization Service Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa
11 Corporate Profile
11.1 Iron Mountain Incorporated
11.1.1 Iron Mountain Incorporated Corporation Information
11.1.2 Iron Mountain Incorporated Business Overview
11.1.3 Iron Mountain Incorporated Pathology Slide Digitization Service Product Features and Attributes
11.1.4 Iron Mountain Incorporated Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.1.5 Iron Mountain Incorporated Pathology Slide Digitization Service Revenue by Product in 2025
11.1.6 Iron Mountain Incorporated Pathology Slide Digitization Service Revenue by Application in 2025
11.1.7 Iron Mountain Incorporated Pathology Slide Digitization Service Revenue by Geographic Area in 2025
11.1.8 Iron Mountain Incorporated Pathology Slide Digitization Service SWOT Analysis
11.1.9 Iron Mountain Incorporated Recent Developments
11.2 EVIDENT Corporation (Pramana)
11.2.1 EVIDENT Corporation (Pramana) Corporation Information
11.2.2 EVIDENT Corporation (Pramana) Business Overview
11.2.3 EVIDENT Corporation (Pramana) Pathology Slide Digitization Service Product Features and Attributes
11.2.4 EVIDENT Corporation (Pramana) Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.2.5 EVIDENT Corporation (Pramana) Pathology Slide Digitization Service Revenue by Product in 2025
11.2.6 EVIDENT Corporation (Pramana) Pathology Slide Digitization Service Revenue by Application in 2025
11.2.7 EVIDENT Corporation (Pramana) Pathology Slide Digitization Service Revenue by Geographic Area in 2025
11.2.8 EVIDENT Corporation (Pramana) Pathology Slide Digitization Service SWOT Analysis
11.2.9 EVIDENT Corporation (Pramana) Recent Developments
11.3 Deciphex
11.3.1 Deciphex Corporation Information
11.3.2 Deciphex Business Overview
11.3.3 Deciphex Pathology Slide Digitization Service Product Features and Attributes
11.3.4 Deciphex Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.3.5 Deciphex Pathology Slide Digitization Service Revenue by Product in 2025
11.3.6 Deciphex Pathology Slide Digitization Service Revenue by Application in 2025
11.3.7 Deciphex Pathology Slide Digitization Service Revenue by Geographic Area in 2025
11.3.8 Deciphex Pathology Slide Digitization Service SWOT Analysis
11.3.9 Deciphex Recent Developments
11.4 HistoWiz, Inc.
11.4.1 HistoWiz, Inc. Corporation Information
11.4.2 HistoWiz, Inc. Business Overview
11.4.3 HistoWiz, Inc. Pathology Slide Digitization Service Product Features and Attributes
11.4.4 HistoWiz, Inc. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.4.5 HistoWiz, Inc. Pathology Slide Digitization Service Revenue by Product in 2025
11.4.6 HistoWiz, Inc. Pathology Slide Digitization Service Revenue by Application in 2025
11.4.7 HistoWiz, Inc. Pathology Slide Digitization Service Revenue by Geographic Area in 2025
11.4.8 HistoWiz, Inc. Pathology Slide Digitization Service SWOT Analysis
11.4.9 HistoWiz, Inc. Recent Developments
11.5 3DHISTECH Ltd.
11.5.1 3DHISTECH Ltd. Corporation Information
11.5.2 3DHISTECH Ltd. Business Overview
11.5.3 3DHISTECH Ltd. Pathology Slide Digitization Service Product Features and Attributes
11.5.4 3DHISTECH Ltd. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.5.5 3DHISTECH Ltd. Pathology Slide Digitization Service Revenue by Product in 2025
11.5.6 3DHISTECH Ltd. Pathology Slide Digitization Service Revenue by Application in 2025
11.5.7 3DHISTECH Ltd. Pathology Slide Digitization Service Revenue by Geographic Area in 2025
11.5.8 3DHISTECH Ltd. Pathology Slide Digitization Service SWOT Analysis
11.5.9 3DHISTECH Ltd. Recent Developments
11.6 Huron Technologies International Inc.
11.6.1 Huron Technologies International Inc. Corporation Information
11.6.2 Huron Technologies International Inc. Business Overview
11.6.3 Huron Technologies International Inc. Pathology Slide Digitization Service Product Features and Attributes
11.6.4 Huron Technologies International Inc. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.6.5 Huron Technologies International Inc. Recent Developments
11.7 CellCarta
11.7.1 CellCarta Corporation Information
11.7.2 CellCarta Business Overview
11.7.3 CellCarta Pathology Slide Digitization Service Product Features and Attributes
11.7.4 CellCarta Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.7.5 CellCarta Recent Developments
11.8 Charles River Laboratories International, Inc.
11.8.1 Charles River Laboratories International, Inc. Corporation Information
11.8.2 Charles River Laboratories International, Inc. Business Overview
11.8.3 Charles River Laboratories International, Inc. Pathology Slide Digitization Service Product Features and Attributes
11.8.4 Charles River Laboratories International, Inc. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.8.5 Charles River Laboratories International, Inc. Recent Developments
11.9 Labcorp Holdings Inc.
11.9.1 Labcorp Holdings Inc. Corporation Information
11.9.2 Labcorp Holdings Inc. Business Overview
11.9.3 Labcorp Holdings Inc. Pathology Slide Digitization Service Product Features and Attributes
11.9.4 Labcorp Holdings Inc. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.9.5 Labcorp Holdings Inc. Recent Developments
11.10 Source BioScience
11.10.1 Source BioScience Corporation Information
11.10.2 Source BioScience Business Overview
11.10.3 Source BioScience Pathology Slide Digitization Service Product Features and Attributes
11.10.4 Source BioScience Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 StageBio
11.11.1 StageBio Corporation Information
11.11.2 StageBio Business Overview
11.11.3 StageBio Pathology Slide Digitization Service Product Features and Attributes
11.11.4 StageBio Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.11.5 StageBio Recent Developments
11.12 Sartorius AG
11.12.1 Sartorius AG Corporation Information
11.12.2 Sartorius AG Business Overview
11.12.3 Sartorius AG Pathology Slide Digitization Service Product Features and Attributes
11.12.4 Sartorius AG Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.12.5 Sartorius AG Recent Developments
11.13 HistologiX
11.13.1 HistologiX Corporation Information
11.13.2 HistologiX Business Overview
11.13.3 HistologiX Pathology Slide Digitization Service Product Features and Attributes
11.13.4 HistologiX Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.13.5 HistologiX Recent Developments
11.14 iHisto
11.14.1 iHisto Corporation Information
11.14.2 iHisto Business Overview
11.14.3 iHisto Pathology Slide Digitization Service Product Features and Attributes
11.14.4 iHisto Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.14.5 iHisto Recent Developments
11.15 Digital Pathology Services
11.15.1 Digital Pathology Services Corporation Information
11.15.2 Digital Pathology Services Business Overview
11.15.3 Digital Pathology Services Pathology Slide Digitization Service Product Features and Attributes
11.15.4 Digital Pathology Services Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.15.5 Digital Pathology Services Recent Developments
11.16 IDEXX Laboratories, Inc.
11.16.1 IDEXX Laboratories, Inc. Corporation Information
11.16.2 IDEXX Laboratories, Inc. Business Overview
11.16.3 IDEXX Laboratories, Inc. Pathology Slide Digitization Service Product Features and Attributes
11.16.4 IDEXX Laboratories, Inc. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.16.5 IDEXX Laboratories, Inc. Recent Developments
11.17 Inotiv, Inc.
11.17.1 Inotiv, Inc. Corporation Information
11.17.2 Inotiv, Inc. Business Overview
11.17.3 Inotiv, Inc. Pathology Slide Digitization Service Product Features and Attributes
11.17.4 Inotiv, Inc. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.17.5 Inotiv, Inc. Recent Developments
11.18 Propath
11.18.1 Propath Corporation Information
11.18.2 Propath Business Overview
11.18.3 Propath Pathology Slide Digitization Service Product Features and Attributes
11.18.4 Propath Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.18.5 Propath Recent Developments
11.19 EPL, Inc.
11.19.1 EPL, Inc. Corporation Information
11.19.2 EPL, Inc. Business Overview
11.19.3 EPL, Inc. Pathology Slide Digitization Service Product Features and Attributes
11.19.4 EPL, Inc. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.19.5 EPL, Inc. Recent Developments
11.20 iBioSpecimen
11.20.1 iBioSpecimen Corporation Information
11.20.2 iBioSpecimen Business Overview
11.20.3 iBioSpecimen Pathology Slide Digitization Service Product Features and Attributes
11.20.4 iBioSpecimen Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.20.5 iBioSpecimen Recent Developments
11.21 Meyer Instruments, Inc.
11.21.1 Meyer Instruments, Inc. Corporation Information
11.21.2 Meyer Instruments, Inc. Business Overview
11.21.3 Meyer Instruments, Inc. Pathology Slide Digitization Service Product Features and Attributes
11.21.4 Meyer Instruments, Inc. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.21.5 Meyer Instruments, Inc. Recent Developments
11.22 Precision for Medicine
11.22.1 Precision for Medicine Corporation Information
11.22.2 Precision for Medicine Business Overview
11.22.3 Precision for Medicine Pathology Slide Digitization Service Product Features and Attributes
11.22.4 Precision for Medicine Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.22.5 Precision for Medicine Recent Developments
11.23 Aragen Bioscience, Inc.
11.23.1 Aragen Bioscience, Inc. Corporation Information
11.23.2 Aragen Bioscience, Inc. Business Overview
11.23.3 Aragen Bioscience, Inc. Pathology Slide Digitization Service Product Features and Attributes
11.23.4 Aragen Bioscience, Inc. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.23.5 Aragen Bioscience, Inc. Recent Developments
11.24 LLS ROWIAK LaserLabSolutions GmbH
11.24.1 LLS ROWIAK LaserLabSolutions GmbH Corporation Information
11.24.2 LLS ROWIAK LaserLabSolutions GmbH Business Overview
11.24.3 LLS ROWIAK LaserLabSolutions GmbH Pathology Slide Digitization Service Product Features and Attributes
11.24.4 LLS ROWIAK LaserLabSolutions GmbH Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.24.5 LLS ROWIAK LaserLabSolutions GmbH Recent Developments
11.25 NationWide Laboratories
11.25.1 NationWide Laboratories Corporation Information
11.25.2 NationWide Laboratories Business Overview
11.25.3 NationWide Laboratories Pathology Slide Digitization Service Product Features and Attributes
11.25.4 NationWide Laboratories Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.25.5 NationWide Laboratories Recent Developments
11.26 ABS Bio, Inc.
11.26.1 ABS Bio, Inc. Corporation Information
11.26.2 ABS Bio, Inc. Business Overview
11.26.3 ABS Bio, Inc. Pathology Slide Digitization Service Product Features and Attributes
11.26.4 ABS Bio, Inc. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.26.5 ABS Bio, Inc. Recent Developments
11.27 Medmain Inc.
11.27.1 Medmain Inc. Corporation Information
11.27.2 Medmain Inc. Business Overview
11.27.3 Medmain Inc. Pathology Slide Digitization Service Product Features and Attributes
11.27.4 Medmain Inc. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.27.5 Medmain Inc. Recent Developments
11.28 BioSpective Inc.
11.28.1 BioSpective Inc. Corporation Information
11.28.2 BioSpective Inc. Business Overview
11.28.3 BioSpective Inc. Pathology Slide Digitization Service Product Features and Attributes
11.28.4 BioSpective Inc. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.28.5 BioSpective Inc. Recent Developments
11.29 Genostaff Co., Ltd.
11.29.1 Genostaff Co., Ltd. Corporation Information
11.29.2 Genostaff Co., Ltd. Business Overview
11.29.3 Genostaff Co., Ltd. Pathology Slide Digitization Service Product Features and Attributes
11.29.4 Genostaff Co., Ltd. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.29.5 Genostaff Co., Ltd. Recent Developments
11.30 BEIJING BIOSYNTHESIS BIOTECHNOLOGY CO., LTD.
11.30.1 BEIJING BIOSYNTHESIS BIOTECHNOLOGY CO., LTD. Corporation Information
11.30.2 BEIJING BIOSYNTHESIS BIOTECHNOLOGY CO., LTD. Business Overview
11.30.3 BEIJING BIOSYNTHESIS BIOTECHNOLOGY CO., LTD. Pathology Slide Digitization Service Product Features and Attributes
11.30.4 BEIJING BIOSYNTHESIS BIOTECHNOLOGY CO., LTD. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.30.5 BEIJING BIOSYNTHESIS BIOTECHNOLOGY CO., LTD. Recent Developments
11.31 Affinity Biosciences LTD
11.31.1 Affinity Biosciences LTD Corporation Information
11.31.2 Affinity Biosciences LTD Business Overview
11.31.3 Affinity Biosciences LTD Pathology Slide Digitization Service Product Features and Attributes
11.31.4 Affinity Biosciences LTD Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.31.5 Affinity Biosciences LTD Recent Developments
11.32 C-Path BV
11.32.1 C-Path BV Corporation Information
11.32.2 C-Path BV Business Overview
11.32.3 C-Path BV Pathology Slide Digitization Service Product Features and Attributes
11.32.4 C-Path BV Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.32.5 C-Path BV Recent Developments
11.33 GENOSS Co., Ltd.
11.33.1 GENOSS Co., Ltd. Corporation Information
11.33.2 GENOSS Co., Ltd. Business Overview
11.33.3 GENOSS Co., Ltd. Pathology Slide Digitization Service Product Features and Attributes
11.33.4 GENOSS Co., Ltd. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.33.5 GENOSS Co., Ltd. Recent Developments
11.34 Fukushima Cell Factory Co., Ltd.
11.34.1 Fukushima Cell Factory Co., Ltd. Corporation Information
11.34.2 Fukushima Cell Factory Co., Ltd. Business Overview
11.34.3 Fukushima Cell Factory Co., Ltd. Pathology Slide Digitization Service Product Features and Attributes
11.34.4 Fukushima Cell Factory Co., Ltd. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.34.5 Fukushima Cell Factory Co., Ltd. Recent Developments
11.35 Mediridge Co., Ltd.
11.35.1 Mediridge Co., Ltd. Corporation Information
11.35.2 Mediridge Co., Ltd. Business Overview
11.35.3 Mediridge Co., Ltd. Pathology Slide Digitization Service Product Features and Attributes
11.35.4 Mediridge Co., Ltd. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.35.5 Mediridge Co., Ltd. Recent Developments
11.36 BioPioneer
11.36.1 BioPioneer Corporation Information
11.36.2 BioPioneer Business Overview
11.36.3 BioPioneer Pathology Slide Digitization Service Product Features and Attributes
11.36.4 BioPioneer Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.36.5 BioPioneer Recent Developments
11.37 Toson Technology Co., Ltd.
11.37.1 Toson Technology Co., Ltd. Corporation Information
11.37.2 Toson Technology Co., Ltd. Business Overview
11.37.3 Toson Technology Co., Ltd. Pathology Slide Digitization Service Product Features and Attributes
11.37.4 Toson Technology Co., Ltd. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.37.5 Toson Technology Co., Ltd. Recent Developments
11.38 Tian You International Co., Ltd.
11.38.1 Tian You International Co., Ltd. Corporation Information
11.38.2 Tian You International Co., Ltd. Business Overview
11.38.3 Tian You International Co., Ltd. Pathology Slide Digitization Service Product Features and Attributes
11.38.4 Tian You International Co., Ltd. Pathology Slide Digitization Service Revenue and Gross Margin (2021-2026)
11.38.5 Tian You International Co., Ltd. Recent Developments
12 Pathology Slide Digitization Service Value Chain and Ecosystem Analysis
12.1 Pathology Slide Digitization Service Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Pathology Slide Digitization Service Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Pathology Slide Digitization Service Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Pathology Slide Digitization Service Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Pathology Slide Digitization Service Market Size Growth Rate by Service Delivery Model, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Pathology Slide Digitization Service Market Size Growth Rate by Specimen and Slide Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Pathology Slide Digitization Service Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Pathology Slide Digitization Service Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Pathology Slide Digitization Service Revenue by Region (US$ Million), 2021-2026
Table 7. Global Pathology Slide Digitization Service Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Pathology Slide Digitization Service Revenue by Players (US$ Million), 2021-2026
Table 10. Global Pathology Slide Digitization Service Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Pathology Slide Digitization Service Revenue, 2025
Table 13. Global Pathology Slide Digitization Service Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Pathology Slide Digitization Service Companies Headquarters
Table 15. Global Pathology Slide Digitization Service Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Pathology Slide Digitization Service Revenue by Type (US$ Million), 2021-2026
Table 19. Global Pathology Slide Digitization Service Revenue by Type (US$ Million), 2027-2032
Table 20. Global Pathology Slide Digitization Service Revenue by Service Delivery Model (US$ Million), 2021-2026
Table 21. Global Pathology Slide Digitization Service Revenue by Service Delivery Model (US$ Million), 2027-2032
Table 22. Global Pathology Slide Digitization Service Revenue by Specimen and Slide Type (US$ Million), 2021-2026
Table 23. Global Pathology Slide Digitization Service Revenue by Specimen and Slide Type (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Pathology Slide Digitization Service Revenue by Application (US$ Million), 2021-2026
Table 26. Global Pathology Slide Digitization Service Revenue by Application (US$ Million), 2027-2032
Table 27. Pathology Slide Digitization Service High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Pathology Slide Digitization Service Growth Accelerators and Market Barriers
Table 31. North America Pathology Slide Digitization Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Pathology Slide Digitization Service Growth Accelerators and Market Barriers
Table 33. Europe Pathology Slide Digitization Service Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Pathology Slide Digitization Service Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Pathology Slide Digitization Service Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Pathology Slide Digitization Service Investment Opportunities and Key Challenges
Table 37. Central and South America Pathology Slide Digitization Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Pathology Slide Digitization Service Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Pathology Slide Digitization Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Iron Mountain Incorporated Corporation Information
Table 41. Iron Mountain Incorporated Description and Major Businesses
Table 42. Iron Mountain Incorporated Product Features and Attributes
Table 43. Iron Mountain Incorporated Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Iron Mountain Incorporated Revenue Proportion by Product in 2025
Table 45. Iron Mountain Incorporated Revenue Proportion by Application in 2025
Table 46. Iron Mountain Incorporated Revenue Proportion by Geographic Area in 2025
Table 47. Iron Mountain Incorporated Pathology Slide Digitization Service SWOT Analysis
Table 48. Iron Mountain Incorporated Recent Developments
Table 49. EVIDENT Corporation (Pramana) Corporation Information
Table 50. EVIDENT Corporation (Pramana) Description and Major Businesses
Table 51. EVIDENT Corporation (Pramana) Product Features and Attributes
Table 52. EVIDENT Corporation (Pramana) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. EVIDENT Corporation (Pramana) Revenue Proportion by Product in 2025
Table 54. EVIDENT Corporation (Pramana) Revenue Proportion by Application in 2025
Table 55. EVIDENT Corporation (Pramana) Revenue Proportion by Geographic Area in 2025
Table 56. EVIDENT Corporation (Pramana) Pathology Slide Digitization Service SWOT Analysis
Table 57. EVIDENT Corporation (Pramana) Recent Developments
Table 58. Deciphex Corporation Information
Table 59. Deciphex Description and Major Businesses
Table 60. Deciphex Product Features and Attributes
Table 61. Deciphex Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Deciphex Revenue Proportion by Product in 2025
Table 63. Deciphex Revenue Proportion by Application in 2025
Table 64. Deciphex Revenue Proportion by Geographic Area in 2025
Table 65. Deciphex Pathology Slide Digitization Service SWOT Analysis
Table 66. Deciphex Recent Developments
Table 67. HistoWiz, Inc. Corporation Information
Table 68. HistoWiz, Inc. Description and Major Businesses
Table 69. HistoWiz, Inc. Product Features and Attributes
Table 70. HistoWiz, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. HistoWiz, Inc. Revenue Proportion by Product in 2025
Table 72. HistoWiz, Inc. Revenue Proportion by Application in 2025
Table 73. HistoWiz, Inc. Revenue Proportion by Geographic Area in 2025
Table 74. HistoWiz, Inc. Pathology Slide Digitization Service SWOT Analysis
Table 75. HistoWiz, Inc. Recent Developments
Table 76. 3DHISTECH Ltd. Corporation Information
Table 77. 3DHISTECH Ltd. Description and Major Businesses
Table 78. 3DHISTECH Ltd. Product Features and Attributes
Table 79. 3DHISTECH Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. 3DHISTECH Ltd. Revenue Proportion by Product in 2025
Table 81. 3DHISTECH Ltd. Revenue Proportion by Application in 2025
Table 82. 3DHISTECH Ltd. Revenue Proportion by Geographic Area in 2025
Table 83. 3DHISTECH Ltd. Pathology Slide Digitization Service SWOT Analysis
Table 84. 3DHISTECH Ltd. Recent Developments
Table 85. Huron Technologies International Inc. Corporation Information
Table 86. Huron Technologies International Inc. Description and Major Businesses
Table 87. Huron Technologies International Inc. Product Features and Attributes
Table 88. Huron Technologies International Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Huron Technologies International Inc. Recent Developments
Table 90. CellCarta Corporation Information
Table 91. CellCarta Description and Major Businesses
Table 92. CellCarta Product Features and Attributes
Table 93. CellCarta Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. CellCarta Recent Developments
Table 95. Charles River Laboratories International, Inc. Corporation Information
Table 96. Charles River Laboratories International, Inc. Description and Major Businesses
Table 97. Charles River Laboratories International, Inc. Product Features and Attributes
Table 98. Charles River Laboratories International, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Charles River Laboratories International, Inc. Recent Developments
Table 100. Labcorp Holdings Inc. Corporation Information
Table 101. Labcorp Holdings Inc. Description and Major Businesses
Table 102. Labcorp Holdings Inc. Product Features and Attributes
Table 103. Labcorp Holdings Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Labcorp Holdings Inc. Recent Developments
Table 105. Source BioScience Corporation Information
Table 106. Source BioScience Description and Major Businesses
Table 107. Source BioScience Product Features and Attributes
Table 108. Source BioScience Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Source BioScience Recent Developments
Table 110. StageBio Corporation Information
Table 111. StageBio Description and Major Businesses
Table 112. StageBio Product Features and Attributes
Table 113. StageBio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. StageBio Recent Developments
Table 115. Sartorius AG Corporation Information
Table 116. Sartorius AG Description and Major Businesses
Table 117. Sartorius AG Product Features and Attributes
Table 118. Sartorius AG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Sartorius AG Recent Developments
Table 120. HistologiX Corporation Information
Table 121. HistologiX Description and Major Businesses
Table 122. HistologiX Product Features and Attributes
Table 123. HistologiX Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. HistologiX Recent Developments
Table 125. iHisto Corporation Information
Table 126. iHisto Description and Major Businesses
Table 127. iHisto Product Features and Attributes
Table 128. iHisto Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. iHisto Recent Developments
Table 130. Digital Pathology Services Corporation Information
Table 131. Digital Pathology Services Description and Major Businesses
Table 132. Digital Pathology Services Product Features and Attributes
Table 133. Digital Pathology Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Digital Pathology Services Recent Developments
Table 135. IDEXX Laboratories, Inc. Corporation Information
Table 136. IDEXX Laboratories, Inc. Description and Major Businesses
Table 137. IDEXX Laboratories, Inc. Product Features and Attributes
Table 138. IDEXX Laboratories, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. IDEXX Laboratories, Inc. Recent Developments
Table 140. Inotiv, Inc. Corporation Information
Table 141. Inotiv, Inc. Description and Major Businesses
Table 142. Inotiv, Inc. Product Features and Attributes
Table 143. Inotiv, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Inotiv, Inc. Recent Developments
Table 145. Propath Corporation Information
Table 146. Propath Description and Major Businesses
Table 147. Propath Product Features and Attributes
Table 148. Propath Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Propath Recent Developments
Table 150. EPL, Inc. Corporation Information
Table 151. EPL, Inc. Description and Major Businesses
Table 152. EPL, Inc. Product Features and Attributes
Table 153. EPL, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. EPL, Inc. Recent Developments
Table 155. iBioSpecimen Corporation Information
Table 156. iBioSpecimen Description and Major Businesses
Table 157. iBioSpecimen Product Features and Attributes
Table 158. iBioSpecimen Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. iBioSpecimen Recent Developments
Table 160. Meyer Instruments, Inc. Corporation Information
Table 161. Meyer Instruments, Inc. Description and Major Businesses
Table 162. Meyer Instruments, Inc. Product Features and Attributes
Table 163. Meyer Instruments, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Meyer Instruments, Inc. Recent Developments
Table 165. Precision for Medicine Corporation Information
Table 166. Precision for Medicine Description and Major Businesses
Table 167. Precision for Medicine Product Features and Attributes
Table 168. Precision for Medicine Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. Precision for Medicine Recent Developments
Table 170. Aragen Bioscience, Inc. Corporation Information
Table 171. Aragen Bioscience, Inc. Description and Major Businesses
Table 172. Aragen Bioscience, Inc. Product Features and Attributes
Table 173. Aragen Bioscience, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Aragen Bioscience, Inc. Recent Developments
Table 175. LLS ROWIAK LaserLabSolutions GmbH Corporation Information
Table 176. LLS ROWIAK LaserLabSolutions GmbH Description and Major Businesses
Table 177. LLS ROWIAK LaserLabSolutions GmbH Product Features and Attributes
Table 178. LLS ROWIAK LaserLabSolutions GmbH Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. LLS ROWIAK LaserLabSolutions GmbH Recent Developments
Table 180. NationWide Laboratories Corporation Information
Table 181. NationWide Laboratories Description and Major Businesses
Table 182. NationWide Laboratories Product Features and Attributes
Table 183. NationWide Laboratories Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. NationWide Laboratories Recent Developments
Table 185. ABS Bio, Inc. Corporation Information
Table 186. ABS Bio, Inc. Description and Major Businesses
Table 187. ABS Bio, Inc. Product Features and Attributes
Table 188. ABS Bio, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. ABS Bio, Inc. Recent Developments
Table 190. Medmain Inc. Corporation Information
Table 191. Medmain Inc. Description and Major Businesses
Table 192. Medmain Inc. Product Features and Attributes
Table 193. Medmain Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Medmain Inc. Recent Developments
Table 195. BioSpective Inc. Corporation Information
Table 196. BioSpective Inc. Description and Major Businesses
Table 197. BioSpective Inc. Product Features and Attributes
Table 198. BioSpective Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. BioSpective Inc. Recent Developments
Table 200. Genostaff Co., Ltd. Corporation Information
Table 201. Genostaff Co., Ltd. Description and Major Businesses
Table 202. Genostaff Co., Ltd. Product Features and Attributes
Table 203. Genostaff Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. Genostaff Co., Ltd. Recent Developments
Table 205. BEIJING BIOSYNTHESIS BIOTECHNOLOGY CO., LTD. Corporation Information
Table 206. BEIJING BIOSYNTHESIS BIOTECHNOLOGY CO., LTD. Description and Major Businesses
Table 207. BEIJING BIOSYNTHESIS BIOTECHNOLOGY CO., LTD. Product Features and Attributes
Table 208. BEIJING BIOSYNTHESIS BIOTECHNOLOGY CO., LTD. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. BEIJING BIOSYNTHESIS BIOTECHNOLOGY CO., LTD. Recent Developments
Table 210. Affinity Biosciences LTD Corporation Information
Table 211. Affinity Biosciences LTD Description and Major Businesses
Table 212. Affinity Biosciences LTD Product Features and Attributes
Table 213. Affinity Biosciences LTD Revenue (US$ Million) and Gross Margin (2021-2026)
Table 214. Affinity Biosciences LTD Recent Developments
Table 215. C-Path BV Corporation Information
Table 216. C-Path BV Description and Major Businesses
Table 217. C-Path BV Product Features and Attributes
Table 218. C-Path BV Revenue (US$ Million) and Gross Margin (2021-2026)
Table 219. C-Path BV Recent Developments
Table 220. GENOSS Co., Ltd. Corporation Information
Table 221. GENOSS Co., Ltd. Description and Major Businesses
Table 222. GENOSS Co., Ltd. Product Features and Attributes
Table 223. GENOSS Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 224. GENOSS Co., Ltd. Recent Developments
Table 225. Fukushima Cell Factory Co., Ltd. Corporation Information
Table 226. Fukushima Cell Factory Co., Ltd. Description and Major Businesses
Table 227. Fukushima Cell Factory Co., Ltd. Product Features and Attributes
Table 228. Fukushima Cell Factory Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 229. Fukushima Cell Factory Co., Ltd. Recent Developments
Table 230. Mediridge Co., Ltd. Corporation Information
Table 231. Mediridge Co., Ltd. Description and Major Businesses
Table 232. Mediridge Co., Ltd. Product Features and Attributes
Table 233. Mediridge Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 234. Mediridge Co., Ltd. Recent Developments
Table 235. BioPioneer Corporation Information
Table 236. BioPioneer Description and Major Businesses
Table 237. BioPioneer Product Features and Attributes
Table 238. BioPioneer Revenue (US$ Million) and Gross Margin (2021-2026)
Table 239. BioPioneer Recent Developments
Table 240. Toson Technology Co., Ltd. Corporation Information
Table 241. Toson Technology Co., Ltd. Description and Major Businesses
Table 242. Toson Technology Co., Ltd. Product Features and Attributes
Table 243. Toson Technology Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 244. Toson Technology Co., Ltd. Recent Developments
Table 245. Tian You International Co., Ltd. Corporation Information
Table 246. Tian You International Co., Ltd. Description and Major Businesses
Table 247. Tian You International Co., Ltd. Product Features and Attributes
Table 248. Tian You International Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 249. Tian You International Co., Ltd. Recent Developments
Table 250. Technologies, Platforms and Infrastructure
Table 251. Distributors List
Table 252. Market Trends and Market Evolution
Table 253. Market Drivers and Opportunities
Table 254. Market Challenges, Risks, and Restraints
Table 255. Research Programs/Design for This Report
Table 256. Key Data Information from Secondary Sources
Table 257. Key Data Information from Primary Sources


List of Figures
Figure 1. Global Pathology Slide Digitization Service Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Brightfield Whole Slide Imaging Product Picture
Figure 3. Fluorescence Whole Slide Imaging Product Picture
Figure 4. Multispectral Imaging Product Picture
Figure 5. Others Product Picture
Figure 6. Global Pathology Slide Digitization Service Market Size Growth Rate by Service Delivery Model, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Centralized Batch Scanning Product Picture
Figure 8. On-site Project Scanning Product Picture
Figure 9. Managed Scanning Product Picture
Figure 10. Others Product Picture
Figure 11. Global Pathology Slide Digitization Service Market Size Growth Rate by Specimen and Slide Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. Histology Tissue Slides Product Picture
Figure 13. Cytology and Hematology Slides Product Picture
Figure 14. Tissue Microarrays Product Picture
Figure 15. Others Product Picture
Figure 16. Global Pathology Slide Digitization Service Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 17. Preclinical and Clinical Trials
Figure 18. Clinical Workflow and Consultation Support
Figure 19. Archival Digitization
Figure 20. Others
Figure 21. Pathology Slide Digitization Service Report Years Considered
Figure 22. Global Pathology Slide Digitization Service Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 23. Global Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 24. Global Pathology Slide Digitization Service Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 25. Global Pathology Slide Digitization Service Revenue-Based Market Share by Region (2021-2032)
Figure 26. Global Pathology Slide Digitization Service Revenue-Based Market Share Ranking (2025)
Figure 27. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 28. Brightfield Whole Slide Imaging Revenue-Based Market Share by Player in 2025
Figure 29. Fluorescence Whole Slide Imaging Revenue-Based Market Share by Player in 2025
Figure 30. Multispectral Imaging Revenue-Based Market Share by Player in 2025
Figure 31. Others Revenue-Based Market Share by Player in 2025
Figure 32. Global Pathology Slide Digitization Service Revenue-Based Market Share by Type (2021-2032)
Figure 33. Global Pathology Slide Digitization Service Revenue-Based Market Share by Service Delivery Model (2021-2032)
Figure 34. Global Pathology Slide Digitization Service Revenue-Based Market Share by Specimen and Slide Type (2021-2032)
Figure 35. Global Pathology Slide Digitization Service Revenue-Based Market Share by Application (2021-2032)
Figure 36. North America Pathology Slide Digitization Service Revenue YoY (US$ Million), 2021-2032
Figure 37. North America Top 5 Players Pathology Slide Digitization Service Revenue (US$ Million) in 2025
Figure 38. North America Pathology Slide Digitization Service Revenue (US$ Million) by Application (2021-2032)
Figure 39. US Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 40. Canada Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 41. Mexico Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 42. Europe Pathology Slide Digitization Service Revenue YoY (US$ Million), 2021-2032
Figure 43. Europe Top 5 Players Pathology Slide Digitization Service Revenue (US$ Million) in 2025
Figure 44. Europe Pathology Slide Digitization Service Revenue (US$ Million) by Application (2021-2032)
Figure 45. Germany Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 46. France Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 47. U.K. Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 48. Italy Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 49. Russia Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 50. Asia-Pacific Pathology Slide Digitization Service Revenue YoY (US$ Million), 2021-2032
Figure 51. Asia-Pacific Top 8 Players Pathology Slide Digitization Service Revenue (US$ Million) in 2025
Figure 52. Asia-Pacific Pathology Slide Digitization Service Revenue (US$ Million) by Application (2021-2032)
Figure 53. Indonesia Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 54. Japan Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 55. South Korea Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 56. Australia Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 57. India Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 58. Indonesia Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 59. Vietnam Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 60. Malaysia Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 61. Philippines Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 62. Singapore Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 63. Central and South America Pathology Slide Digitization Service Revenue YoY (US$ Million), 2021-2032
Figure 64. Central and South America Top 5 Players Pathology Slide Digitization Service Revenue (US$ Million) in 2025
Figure 65. Central and South America Pathology Slide Digitization Service Revenue (US$ Million) by Application (2021-2032)
Figure 66. Brazil Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 67. Argentina Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 68. Middle East and Africa Pathology Slide Digitization Service Revenue YoY (US$ Million), 2021-2032
Figure 69. Middle East and Africa Top 5 Players Pathology Slide Digitization Service Revenue (US$ Million) in 2025
Figure 70. Middle East and Africa Pathology Slide Digitization Service Revenue (US$ Million) by Application (2021-2032)
Figure 71. GCC Countries Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 72. Israel Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 73. Egypt Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 74. South Africa Pathology Slide Digitization Service Revenue (US$ Million), 2021-2032
Figure 75. Pathology Slide Digitization Service Value Chain Mapping
Figure 76. Channels of Distribution (Direct Vs Distribution)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed